Sherri C. Oberg
Sherri C. Oberg has more than 20 years of experience leading private as well as public, NASDAQ listed companies. Most recently, she was the President and CEO of Acusphere, an emerging pharmaceutical company she co-‐founded out of the basement of her house. She started with a vision for transforming the way coronary artery disease is managed, hired a team of chemical engineers to invent a novel microparticle technology, which created four patented drug candidates for cardiology, cancer, pain and asthma that entered human clinical trials. One of these drug candidates completed all three phases of human testing, commercial manufacturing scale-‐up and regulatory submissions for approval in the US and Europe. Under her leadership, Acusphere raised over $300 million, including $100 million in venture capital, an initial public offering (IPO), more than $200 million in various public equity transactions, international partnerships and joint ventures around specific product and/or geographic rights. Sherri began her career in venture capital, first at Inco Venture Capital Management and then Aegis Venture Funds. She serves on the Board of Trustees at Dartmouth College, where she is Chair of the Audit Committee with oversight responsibility over $1 billion in operations and a $4.5 million endowment. She received a BA from Dartmouth College and MBA from the Tuck School of Business.